Radiopharmaceuticals for Assessing ABC Transporters at the Blood-Brain Barrier

  • R. M. Raaphorst
  • , A. D. Windhorst
  • , P. H. Elsinga
  • , N. A. Colabufo
  • , A. A. Lammertsma
  • , G. Luurtsema*
  • *Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

25 Citations (Scopus)
127 Downloads (Pure)

Abstract

ABC transporters protect the brain by transporting neurotoxic compounds from the brain back into the blood. P-glycoprotein (P-gp) is the most investigated ABC (efflux) transporter, as it is implicated in neurodegenerative diseases such as Alzheimer's disease. Altered function of P-gp can be studied in vivo, using Positron Emission Tomography (PET). To date, several radiopharmaceuticals have been developed to image P-gp function in vivo. So far, attempts to image expression levels of P-gp using radiolabeled P-gp inhibitors have not been successful. Improved knowledge of compound behavior toward P-gp from in vitro studies should increase predictability of in vivo outcome.

Original languageEnglish
Pages (from-to)362-371
Number of pages10
JournalClinical Pharmacology & Therapeutics
Volume97
Issue number4
DOIs
Publication statusPublished - Apr-2015

Keywords

  • POSITRON-EMISSION-TOMOGRAPHY
  • CANCER RESISTANCE PROTEIN
  • P-GLYCOPROTEIN FUNCTION
  • DRUG EFFLUX TRANSPORTERS
  • IN-VIVO EVALUATION
  • MULTIDRUG-RESISTANCE
  • PARKINSONS-DISEASE
  • TARIQUIDAR XR9576
  • PET
  • INHIBITOR

Fingerprint

Dive into the research topics of 'Radiopharmaceuticals for Assessing ABC Transporters at the Blood-Brain Barrier'. Together they form a unique fingerprint.

Cite this